Addition of Local Hepatic Therapy to Sorafenib in Patients with Advanced Hepatocellular Carcinoma (Stage BCLC C)

Laura Schmidt a  Mark op den Winkel a  Katharina Fischer a  Gundula Straub a  Barbara Rauch a  Philipp Marius Paprottka b  Burkhard Göke a  Frank Thomas Kolligs a

a Department of Internal Medicine II and b Department of Clinical Radiology, University Hospital Munich, Campus Großhadern, Munich, Germany

Key Words
Hepatocellular carcinoma · Chemoembolization · Sorafenib · BCLC

Abstract
Background/Aims: For most patients with hepatocellular carcinoma (HCC), diagnosis is invariably done only in the advanced stages of the disease. For advanced, non-metastatic stage, standard therapy is transarterial chemoembolization (TACE). For metastatic disease, the recommended therapy is systemic treatment with sorafenib. In this study, we evaluated the benefit of an additional local hepatic treatment for patients with advanced metastatic disease. Methods: In a retrospective study, we assessed the overall survival (OS), time to progression (TTP), and disease control rate (DCR) in 37 patients with metastasized HCC treated with sorafenib. Sixteen patients received additional local therapy, while 21 patients received only sorafenib. Results: Median OS of patients with combined therapy was significantly higher with 25 months (95% CI: 13.7–36.3 months) as compared to 11 months (95% CI: 6.2–15.8 months) in patients treated with sorafenib alone. TTP was 7 months (95% CI: 5.3–8.7 months) compared to 5 months (95% CI: 3–7 months) and DCR was 87 versus 72% after 3 months and 31 versus 22% after 9 months. Conclusion: These data suggest that control of the liver tumor burden by local therapy in combination with sorafenib might prove beneficial for metastasized HCC. Randomised studies are needed to confirm this exploratory finding.

Introduction
Hepatocellular carcinoma (HCC) is the sixth most prevalent malignancy and the third most frequent cause of cancer-related death worldwide [1]. In recent years, surveillance programs have led to a higher rate of detection of HCC in earlier disease stages [1, 2]. However, in most cases HCC is still diagnosed in advanced stages. According to the AASLD (American Association for the Study of Liver Diseases) and the EASL (European Association for the study of the liver) practice guidelines, transarterial chemoembolization (TACE) is the recommended treatment strategy for patients with multinodular disease limited to the liver. For patients with extrahepatic spread of HCC, systemic treatment with sorafenib is recommended [1–3]. Some studies have assessed the efficacy of a combined treatment with TACE and sorafenib in advanced tumour stage compared to...
TACE alone [4–6]. However, these studies recruited patients usually amenable only to TACE [4, 5].

Prognosis is poor at the metastatic stage. However, in most cases, the cause of death is intrahepatic progression and liver failure [7]. Patients in the metastatic stage treated with sorafenib might therefore benefit from an additional local hepatic treatment. In this retrospective study, we assessed the outcome of patients with metastasized HCC treated with sorafenib plus TACE compared to patients treated only with sorafenib.

Methods

Patients

In the time between 2006 and 2012, 37 patients with HCC at advanced metastatic stage treated at our hospital according to our institutional and interdisciplinary treatment protocol were enrolled. All patients had HCC diagnosed either histologically (19 patients) or by radiologic criteria (18 patients) according to AASLD guidelines [2]. Their medical charts were retrospectively reviewed. We selected 16 patients who were treated with local hepatic treatment (11 patients treated with TACE, 3 treated with radioembolization and 2 patients treated with TACE and radioembolization) and sorafenib simultaneously. We matched a control group of 21 patients who were treated with sorafenib alone. Patients were matched by gender (81% male and 19% female patients in each group), age (median age was 61 in the combined group and 65 in the sorafenib group), presence of liver cirrhosis (10 patients in the combined vs. 14 patients in the sorafenib group), Child Pugh status (7 vs. 10 patients with Child Pugh A, 3 vs. 4 patients with Child Pugh B in the combined vs. the sorafenib group only), primary liver tumour volume (median of 11.5 vs. 12% in the combined vs. the sorafenib group), location of metastasis (8 patients had lung metastasis in the combined group and 7 patients in the sorafenib only group) and exposed to prior therapies such as resection, radiofrequency ablation, TACE (50% of patients in the combined group and 57% patients in the sorafenib group had a history of HCC therapy prior to the current one).

Treatment

TACE and Selective Internal Radiotherapy (SIRT)

TACE was performed by the department of interventional radiology by injection of an emulsion of epirubicin and lipiodol into tumour-feeding vessels. Patients underwent the procedure every 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of TACE was 8–12 weeks depending on the presence of tumour activity in the follow up CT or MRI result (median of numbers of
Etiology of liver cirrhosis in both groups was mainly chronic alcohol abuse and viral hepatitis; in two patients, of the sorafenib group liver cirrhosis was due to hemochromatosis; in seven cases, cirrhosis was cryptogenic. Among those patients without liver cirrhosis, three patients of both groups had steatosis hepatis, one patient in the combined treatment group had chronic HBV, and one patient of the sorafenib group had histologically diagnosed fibrosis for unknown reason. In the other patients either no liver disease could be diagnosed or data was lacking. All patients had a good ECOG performance status (Eastern Cooperative Oncology group) 0 to 1. Median liver tumour burden was 11.5% in the combination and 12% in the sorafenib group. Twelve patients in each group had more than 3 liver lesions. Location of metastasis was mainly lung (8 of 16 patients in the combination and 7 of 21 patients in the sorafenib group) and lymph nodes (6 of 16 and 15 of 21 patients). The majority of patients in both groups had singular metastasis (12 and 16 patients). The median of the whole size of all metastasis was 2.5 cm (combination group) and 2.0 cm (sorafenib group). Partial portal vein thrombosis was observed in 12.5% of the patients (2 patients) in the combined group and in 28.6% of the sorafenib patients (6 patients), complete portal vein thrombosis was observed in 2 patients of the sorafenib only group. Median AFP level was elevated in both groups (147 and 221 ng/ml). Prior therapies comprised in both groups resection, RFA (radiofrequency ablation) or TACE.

| Table 1. Baseline patient and tumour characteristics at the time of first diagnosis of metastases |
|-----------------------------------------------|-----------------------------------------------|----------------|
|                                              | Sorafenib + TACE/SIRT | Sorafenib | p value |
| Patients, n                                  | 16                             | 21          |         |
| Gender, n (%)                                |                                |            |         |
| Male                                         | 13 (81)                        | 17 (81)    | 0.982   |
| Female                                       | 3 (19)                         | 4 (19)     |         |
| Age, years, mean ± SD (min–max)              | 61±9 (46–76)                   | 65±9 (40–79) | 0.204 |
| Presence of liver cirrhosis, n (%)           | 10 (62.5)                      | 14 (66.7)  | 0.943   |
| Child Pugh score                             |                                |            |         |
| A                                            | 7                              | 10         | 0.705   |
| B                                            | 3                              | 4          |         |
| Albumin, g/dl (median)                       | 4.2                            | 4.1        |         |
| Bilirubin, mg/dl (median)                    | 1.1                            | 1.1        |         |
| INR                                          | 1.1                            | 1.1        |         |
| Hepatic encephalopathy                       | 0                              | 0          |         |
| Ascites                                      | 2                              | 4          |         |
| None                                         | 14                             | 17         |         |
| Moderate                                     | 1                              | 2          |         |
| Severe                                       | 1                              | 2          |         |
| Etiology of liver cirrhosis, n (%)           |                                |            |         |
| HCV                                          | 1 (10)                         | 3 (21)     |         |
| HBV                                          | 2 (20)                         | 2 (14)     |         |
| Chronic alcohol abuse                        | 3 (30)                         | 3 (21)     |         |
| Alcohol abuse and HCV                        | 1 (10)                         | –          |         |
| Hemochromatosis                              | –                              | 2 (14)     |         |
| Cryptogenic                                  | 3 (30)                         | 4 (28)     |         |
| Portal vein thrombosis (partial/complete)    | 2/0                            | 6/2        | 0.181   |
| Location of metastases, n (%)                |                                |            |         |
| Lung                                         | 8 (50)                         | 7 (33)     | 0.663   |
| Non-lung                                     | 8 (50)                         | 14 (67)    |         |
| Primary liver tumour volume, n (%)           |                                |            |         |
| Median                                       | 11.5                           | 12         | 0.723   |
| <10%                                         | 8 (50)                         | 9 (43)     |         |
| 10–25%                                       | 4 (25)                         | 7 (33)     |         |
| >25%                                         | 4 (25)                         | 5 (24)     |         |
| Patients with prior therapy, n (%)           | 8 (50)                         | 12 (57)    | 0.666   |
| AFP, ng/ml (median)                          | 147.5 (3.5–5,573)              | 221.5 (4.9–63,837) | 0.140  |
Overall Survival

As shown in figure 1a, patients treated with local hepatic therapy (TACE/SIRT) in addition with sorafenib showed a significantly increased median overall survival time of 25 months (95% confidence interval: 13.7–36.3 months) as compared to patients treated with sorafenib alone (11 months, 95% CI: 6.2–15.8 months) (p = 0.042). After 6 months of follow-up, survival rates were 94% (combination group) versus 90% (sorafenib group), and 75 versus 47% after 12 months of follow-up (fig. 1b). At the end of our evaluation 6 patients from the combination group and 2 patients from the sorafenib group were still under treatment.

To avoid a bias due to the presence of more patients with partial and complete portal lacking complete PVT and for a cohort lacking both complete and partial PVT, we observed for both cohorts a significant better OS in the combined treatment group (fig. 2).

Time to Progression

Patients treated with combined therapy seemed to progress more slowly median time to progression of 7 months (95% CI: 5.3–8.7 months) versus 5 months (95% CI: 3–7 months); however, this difference was not significant (p = 0.531) (fig. 3a). Median time to intrahepatic progression was 7 months (95% CI: 0–15.23 months) versus 8 months (95% CI: 5.96–10.04 months) in the combined versus sorafenib only group (fig. 3b). Median time to extrahepatic progression was 11 months (95% CI: 2.68–19.32 months) in the combined group versus 12 months (95% CI: 0–26.53 months) in the sorafenib only group (fig. 3c). There were neither statistically significant differences in the median time to extrahepatic (p = 0.701) nor in the time to intrahepatic progression (p = 0.938) between the two treatment groups.

Response Evaluation

Patients treated with combined therapy seemed to show a higher rate of disease stabilisation and more partial responses (although not statistically significant). Disease progression seemed to be delayed at 3, 6, and 9 months compared to the sorafenib group (fig. 4a–c). After 12 months there was only a slight difference between the two groups (fig. 4d). Disease control rate (= complete remission plus partial response plus stable disease) after 3, 6, 9, and 12 months was always higher in the combined treatment group compared to the sorafenib group (fig. 5).
Fig. 2. Kaplan-Meier analysis of overall survival for cohorts without complete PVT and without partial or complete portal vein thrombosis (PVT). To avoid a bias due to the presence of complete PVT in the sorafenib group, data was calculated for a cohort without complete (= total) PVT still showing a significant better OS in the combined group (p = 0.031). Data was also calculated for a cohort without any PVT also showing a significant better OS for the combined group (p = 0.05).

Fig. 3. Kaplan-Meier analysis for time to progression. a shows time to overall progression. The median time to overall progression was 7 months (95% CI: 5.3–8.7 months) in the combined group and 5 months (95% CI: 3–7 months) in the sorafenib group and this difference was not significant (p = 0.531). Time to intrahepatic progression is shown in b. The median time to intrahepatic progression was 7 months (95% CI: 0–15.23 months) versus 8 months (95% CI: 5.96–10.04 months) in the combined versus the sorafenib-only group (p = 0.938).
Fig. 3. Kaplan-Meier analysis for time to progression. Time to extrahepatic progression is shown in c. The median time to extrahepatic progression was 11 months (95% CI: 2.68–19.32 months) in the combined group versus 12 months (95% CI: 0–26.53 months) in the sorafenib-only group (p = 0.701).

Fig. 4. Therapy response evaluation. Figure 4 shows the percentage of partial responses, stable diseases and progressive diseases after 3, 6, 9 and 12 months according to RECIST 1.0. There was no case of complete remission in both groups. This evaluation was only performed for patients with sufficient data at these time points. Few patients could not be considered due to drop-off, loss-to-follow-up.
Hand-foot-skin reactions due to sorafenib occurred in 25.8% of the patients in the combined group and only in 4.8% in the sorafenib only group. Accordingly, dose reductions had to be done more often in the combined group (25% of the patients in the combined group vs. in 9.5% of the patients assigned to sorafenib only). The combined treatment was well tolerated by the small number of SIRT patients, 3 of 5 patients had SIRT twice, but dose reduction of sorafenib was also necessary in 3 of 5 patients of this group.

The Median Child Pugh score at the beginning of treatment was 5 points in each group; even during the course of treatment (Child Pugh score was assessed at each staging), there was no significant difference (p = 0.328) between the two groups (online suppl. fig. 1; for all online suppl. material, see www.karger.com/doi/10.1159/000367686). Also, changes of INR over time were not statistically different (p = 0.841). Median bilirubin at the beginning of treatment was similar (1.05 mg/dl in the combined and 1.1 mg/dl in the sorafenib group). However, bilirubin increased significantly to higher levels in the sorafenib group during treatment (p = 0.049). In the combined group, the median AFP level decreased at the beginning of treatment but increased during the course of treatment; conversely, it increased continuously in the sorafenib group (p < 0.001) (online suppl. fig. 2).

**Discussion**

For HCC patients in the advanced metastatic stage (BCLC C, Barcelona Clinic Liver Cancer Group), guidelines recommend systemic treatment with the multikinase inhibitor sorafenib [2, 3]. A major activity of sorafenib is the inhibition of neoangiogenesis, thereby arresting tumour growth by acting on growth factor receptors like VEGFR and PDGFR, Raf signalling and c-Kit [10, 11]. Its efficacy has been demonstrated in two placebo-controlled, randomised phase III trials [12, 13]. The multicenter, double-blind SHARP study, carried out on 602 patients, showed a median overall survival of 10.7 months after treatment with sorafenib compared to 7.9 months in the placebo group [12]. The Asia Pacific study assessed a median overall survival of 6.5 vs. 4.2 months [13]. Safety data were reproduced in the large phase IV GIDEON study [14].
Transarterial chemoembolisation has become the standard treatment for patients in the non-metastatic stage not suitable for curative therapy like resection, transplantation and image-guided tumour ablation [1, 15].

Several large studies have reported a survival benefit from TACE for patients in an intermediate stage of disease (BCLC B: multinodular tumour lesions, performance status 0, Child Pugh A-B) [16–19]. Less data is available for a survival benefit after treatment with selective internal radiotherapy (SIRT) [20–22].

A single-centre prospective study of 80 Child Pugh A patients in the BCLC stage B with HCV associated HCC showed a benefit of sorafenib therapy versus placebo following TACE treatment (TTP of 9.2 vs. 4.9 months) [23]. Similar results were observed in a Japanese and Korean phase III study, where 458 patients in the non-metastatic stage with Child Pugh A received either sorafenib or placebo following TACE treatment. The median survival period after a sequential therapy of TACE and sorafenib was 29.7 months (however, the median survival after placebo treatment was not assessed). Regarding TTP, there was a slight difference of 5.4 versus 3.7 months between the sorafenib and the placebo group [24]. It was recently reported in two phase II trials that the combination of TACE and sorafenib at the same time is well tolerated by patients in the intermediate stage (BCLC B) and advanced metastatic stage (BCLC C) [5, 25, 26]. However, overall survival was not assessed. There are recent studies that showed that patients in the intermediate stage of disease treated with TACE might benefit from an additional simultaneous systemic therapy [4, 5, 27, 28]. A reason for the benefit of combination therapy might be that sorafenib inverses the proangiogenic effect of TACE treatment. The safety of combined treatment was shown in a large randomised phase II trial (SPACE study) [29]. This study, which enrolled 307 HCC patients in the advanced non-metastatic stage who were randomised in a group treated simultaneously with TACE and sorafenib or in a group treated with TACE and placebo, showed a slight benefit of the combined therapy regarding TTP (median TTP in the 50th percentile 196 vs. 166 days, 112 vs. 88 in the 25th percentile and 285 vs. 224 in the 75th percentile in the sorafenib vs. placebo group, HR 0.797) but (not yet) a significant difference in OS [29].

Cause of death for patients in the metastatic stage is rather due to intrahepatic disease progression with consecutive liver failure than due to extrahepatic disease progression [7]. An additional local hepatic therapy for patients treated with sorafenib might improve the outcome for patients in the metastatic stage. We assessed the benefit of combination therapy of sorafenib with local hepatic treatment for patients in the advanced metastatic stage (BCLC C) in a retrospective study of 37 patients. Regarding the baseline patient and tumour characteristics including age, gender, presence of cirrhosis, Child Pugh Score, presence of portal vein thrombosis, and liver tumour burden, there were no significant differences between the two treatment groups. We observed a significant higher overall survival of 25 months in the combination group compared to 11 months after sorafenib treatment alone. Survival time for patients under sorafenib treatment was similar to the SHARP study result [12]. The retrospective study by Qu et al., carried out on 45 patients of HCC in the intermediate and advanced stages, observed a similar overall survival of 27 months after combined TACE and sorafenib treatment compared to 17 months after TACE treatment alone [4].

Patients with complete portal vein thrombosis are usually not treated by TACE and are supposed to have a worse prognosis. In order to prove that the worse prognosis of the sorafenib only group is not due to the presence of more patients with partial and complete portal vein thrombosis in this group we calculated the data for a cohort lacking complete portal vein thrombosis and for a cohort lacking any type of portal vein thrombosis. We assessed a significant better OS in the combined group demonstrating that this is not due to the presence of complete PVT in the sorafenib group.

We observed a higher disease control rate in the combination group after 12 months of follow-up. In our study, the disease seemed to progress more slowly after combined treatment compared to sorafenib treatment alone 7 months (95% CI: 5.3–8.7) versus 5 months (95% CI: 3–7). However, this difference regarding the TTP was not statistically significant between the two therapy arms. Accordingly, there was a significant difference neither in the intrahepatic nor in the extrahepatic progress. TTP measures the time until the first progression and the effect of combined treatment might be seen later during time course. Accordingly, although there was no significant difference in the time course of liver function, AFP levels increased significantly faster in the sorafenib-only group. This might indicate a faster progress in the sorafenib group over the course of treatment independently of the liver function. This is supported by the higher disease control rate in the combined group.

The main limiting factors of our study are the small number of patients and the retrospective setting. This
may have caused the missing of some data and a bias in some cases. The main baseline characteristics at the begin-
ing of treatment however were not statistically signif-
ificant between the two groups. During the time course
of treatment, some laboratory results could not be as-
sessed for all patients. The decision for a combined or
sorafenib only treatment was made individually based
on clinical criteria. About 56.2% of patients in the com-
bination group versus 38.1% in the sorafenib group
showed a metastatic stage when first diagnosed for HCC.
Patients who were first diagnosed at the metastatic stage
might have been offered a combined treatment rather
than sorafenib treatment alone. Patients who showed
disease progression after prior therapies might have
rather received sorafenib alone rather than the combi-
nation. However, the number of patients with prior
therapies was not significantly different in both groups
(8 vs. 12 patients in the combined vs. the sorafenib
group). Although more dose reductions had to be done
in the combination group (due to hand-foot-skin reac-
tion) than in the sorafenib group (25 vs. 9.5%), patients
showed a higher rate of therapy response in the com-
bination group versus 38.1% in the sorafenib group
(25 vs. 9.5%), patients showed a metastatic stage when first diagnosed for HCC. Patients who were first diagnosed at the metastatic stage might have been offered a combined treatment rather than sorafenib treatment alone. Patients who showed disease progression after prior therapies might have rather received sorafenib alone rather than the combination. However, the number of patients with prior therapies was not significantly different in both groups (8 vs. 12 patients in the combined vs. the sorafenib group). Although more dose reductions had to be done in the combination group (due to hand-foot-skin reaction) than in the sorafenib group (25 vs. 9.5%), patients showed a higher rate of therapy response in the combination group.

References

1 Forner A, Llovet JM, Bruix J: Hepatocellular
2 Bruix J, Sherman M: Management of hepatocel-
3 EASL-EORTC clinical practice guidelines: man-
4 Qu XD, Chen CS, Wang JH, Yan ZP, Chen
    JM, Gong GQ, Liu QX, Luo JI, Liu LX, Liu R, Qian S: The efficacy of TACE combined
    analysis of START: study in Asia of the combination of TACE (transcatheter arterial che-
    moembolisation) with sorafenib in patients with hepatocellular carcinoma trial. Int J Can-
    scatheter chemoembolisation and bronchial arterial chemo infusion in the treatment of hepatocel-
7 Uka K, Aikata H, Takaki S, Shinkaw a H, Jeong
    SC, Yamashina K, Hiratsuka A, Kodama H, Takahashi S, Chayama K: Clinical features and
    prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J
8 Therasse P, Arbuck SG, Eisenhauer EA, Wan-
    ders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Chris-
    tian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tu-
    mors. European Organization for Research and Treatment of Cancer, National Cancer
    Institute of the United States, National Can-
9 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz
10 Chang YS, Adnane J, Trail PA, Levy J, Hen-
    derson A, Xie D, Bortoloni E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA,
    Taylor IC, Lynch M, Wilhim S: Sorafenib (BAY 43–9006) inhibits tumor growth and
    vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Can-
    cer Chemother Pharmacol 2007;59:561–574.
11 Wilhim SM, Adnane L, Newell P, Villanueva
    A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that tar-
    gets both Raf and VEGF and PDGF receptor
12 Llovet JM, Ricci S, Mazzaferro V, Hilgard P,
    tion of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafe
    nib) non-interventional study. Int J Clin
15 Bruix J, Sala M, Llovet JM: Chemoemboliza-
    tion for hepatocellular carcinoma. Gastroen-
    terology 2004;127:S179–S188.

Conclusion

Recent studies showed that HCC patients in the inter-
mediate stage of disease treated with TACE might benefit of an additional systemic therapy. A reason for that might be that sorafenib inverses the proangiogenic effect of TACE treatment. Cause of death for patients in the meta-
static stage is intrahepatic rather than extrahepatic pro-
gression of disease. Our study suggests that patients in the metastatic stage of disease might benefit from local treat-
ment of the primary liver lesions in addition to systemic therapy because we observed a significantly higher OS af-
fer combined treatment. However, studies with higher

Acknowledgements

There is no external funding for this study. Conceived and de-
signed study: LS, MODW, FTK, BG. Performed study: LS, KF, FTK. Contributed materials/analysis tools: MODW, GS, BR, PMP. This work is part of the thesis of KF.


